RxDoctor Payments Data

William McCary, MD

Otolaryngology · Huntsville, ALNPI 1477644078

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,117 of the $6,101 with a category attached, or 83.9%. 18 manufacturers reported payments, led by Aerin Medical Inc. at 24.0% of the total. 2025 is the largest year on record at $1,991, 3.5 times the $562 reported in 2019.

$6,101in general payments, 2019–2025

Across 158 payments — averaging $38.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aerin Medical Inc.$1K
  • Stryker$1K
  • Optinose US, Inc.$953
  • Sanofi$670
  • Regeneron Healthcare Solutions, Inc.$633
  • GSK$441
  • plus $823 from 12 others

What the payments were for

  • Travel & lodging$95016%
  • Food & beverage$5,11784%
  • Education$341%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,101 in reported general payments places this provider in the 80th percentile of 155 otolaryngology providers in Alabama.

See all otolaryngology providers in Alabama

Medicare billing

Part B allowed, 2024
$159,373
Medicare patients
512
Services billed
2,113

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Epinephrine13$3,324
Fluticasone Propionate102$1,746
Famotidine137$1,497
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth12$1,379
Ipratropium Bromide37$1,053
Fluocinolone Acetonide Oil21$990
Levothyroxine Sodium18$857
Azelastine Hcl37$820
Pilocarpine Hcl13$797
Omeprazole59$731
Indapamide26$436
Doxycycline Hyclate48$428
Montelukast Sodium26$378
Mupirocin21$309
Cefdinir12$277

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USAEpinephrine$14$3,32413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 155 otolaryngology providers in Alabama.

Other otolaryngology in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →